Welcome to our dedicated page for Axogen SEC filings (Ticker: AXGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Axogen, Inc. (NASDAQ: AXGN) filings with the U.S. Securities and Exchange Commission, along with AI-assisted summaries to help interpret key disclosures. Axogen is a Minnesota-incorporated medical technology company focused on peripheral nerve repair and regeneration, and its filings offer detailed insight into financial performance, regulatory milestones, and corporate governance.
Through Axogen’s annual reports on Form 10-K and quarterly reports on Form 10-Q, readers can review audited and interim financial statements, risk factors, management’s discussion and analysis, and information on its portfolio of peripheral nerve repair products, including Avance (acellular nerve allograft-arwx), Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. These reports also discuss regulatory processes, reimbursement trends, and non-GAAP measures such as EBITDA and Adjusted EBITDA.
Current reports on Form 8-K capture material events, such as Axogen’s announcements regarding FDA review timelines and approval of the Biologics License Application for Avance, quarterly financial results, changes to executive compensation arrangements, and outcomes of annual shareholder meetings. Regulation FD disclosures within 8-K filings often furnish press releases and investor presentations related to earnings and regulatory updates.
Investors can also use this page to track proxy materials and shareholder vote results on matters like director elections, long-term incentive plans, advisory votes on executive compensation, and auditor ratification. Where available, Form 4 and other insider transaction filings can be consulted to monitor trading activity by directors and officers.
The platform’s AI-powered tools summarize lengthy filings, highlight important sections, and surface items such as Avance BLA developments, risk factor changes, and capital structure information, helping readers navigate Axogen’s SEC reporting more efficiently.
Vanguard Capital Management reports beneficial ownership of 2,659,776 shares of Axogen Inc common stock, representing 5.12% of the class.
The Schedule 13G states Vanguard has sole voting power for 368,213 shares and sole dispositive power for 2,659,776 shares. The filing attributes holdings to Vanguard funds and managed accounts. The form is signed 04/29/2026.
Axogen, Inc. will hold its 2026 Annual Meeting of Shareholders as a virtual-only audio webcast on June 23, 2026 at 8:30 a.m. Eastern time. Holders of 53,177,824 common shares outstanding as of April 24, 2026 may vote on electing eight directors, ratifying Deloitte & Touche LLP as independent auditor, and approving a non-binding advisory vote on executive pay. The proxy highlights 2025 performance, including 20.2% revenue growth and improved EBITDA, as well as FDA approval of the biologics license application for Avance as an acellular nerve scaffold. It also details board independence, committee structure, ownership levels, equity plans and pay-for-performance incentive design for named executive officers.
Axogen, Inc. reported strong top-line growth but a larger net loss for the quarter ended March 31, 2026. Revenue rose to $61,457, up 26.6% from the prior year period, driven mainly by higher unit volumes and pricing.
Gross profit increased to $46,189 and gross margin improved to 75.2%, helped by lower inventory write-offs and shipping costs. Operating expenses grew to $49,021 as the company expanded sales, marketing and R&D, resulting in a loss from operations of $2,832.
Net loss widened to $19,584, largely due to a $16,849 loss on extinguishment of debt after Axogen used $69,707 of proceeds from a $133,252 equity offering to repay and terminate its Credit Facility. Cash, cash equivalents and investments increased to $101,601, and management believes this liquidity and product sales will fund operations for at least the next twelve months.
Axogen, Inc. reported strong first quarter 2026 results and raised its full-year 2026 revenue guidance to at least 20% growth, or $270 million. Q1 2026 revenue was $61.5 million, up 26.6% from $48.6 million a year earlier, with gross margin improving to 75.2% from 71.9%.
The company recorded a GAAP net loss of $19.6 million (–$0.38 per share), largely driven by a $16.8 million loss on extinguishment of debt. On a non‑GAAP basis, Axogen reported adjusted net income of $4.1 million ($0.07 per diluted share) and adjusted EBITDA of $5.7 million, a 9.3% margin.
Cash, restricted cash, and investments rose to $103.6 million as of March 31, 2026, from $45.5 million at year‑end 2025, aided by an upsized public offering of 4.6 million shares that generated $133.3 million in net proceeds. The company used $69.7 million of these proceeds to fully repay and terminate its Oberland loan facility. Management expects 2026 gross margin between 74% and 76% and to be free cash flow positive for the full year.
The Vanguard Group files an amendment to Schedule 13G disclosing zero beneficial ownership of Axogen Inc common stock. The filing states an amount beneficially owned: 0 and percent of class: 0%. It explains an internal realignment adopted on 01/12/2026 that prompted disaggregated reporting by certain Vanguard subsidiaries.
Axogen, Inc. Chief Innovation Officer Erick Wayne DeVinney exercised restricted stock units and made related share transactions. On March 16, 2026, 17,938 restricted stock units vested and were converted into an equal number of common shares. Of these, 2,870 shares were withheld by Axogen at $32.84 per share to cover tax obligations, which the company states is not an open-market sale. DeVinney also sold 5,221 common shares in an open-market transaction at $32.84 per share. Following these transactions, he directly holds 262,781 shares of Axogen common stock.
Axogen, Inc. CFO Lindsey Marie Hartley reported routine equity compensation activity tied to restricted stock units (RSUs) vesting on March 16, 2026. She exercised RSUs covering 9,000 shares of common stock, consistent with the plan that each RSU delivers one share when it vests.
To satisfy tax withholding obligations, the issuer withheld 3,542 shares of common stock at $32.84 per share rather than executing any open-market sale. After these RSU conversions and tax withholdings, Hartley holds 60,734 shares of Axogen common stock directly.
Axogen, Inc.’s Chief Marketing Officer, Jens Kemp, reported equity compensation changes and related tax-withholding transactions. On February 26, 2026, he was granted 23,000 restricted stock units (RSUs) and 50,670 shares of common stock as awards at no purchase price.
The RSUs vest fully on February 26, 2030, with 50% vesting on February 26, 2028 and 25% vesting on each of the next two yearly anniversaries. To cover withholding tax from vesting PSUs and RSUs, the issuer withheld 15,414 shares at $31.90 and 2,952 shares at $30.65, and no shares were sold by Kemp. Following these transactions, he directly holds 76,451 shares of common stock and 23,000 RSUs, and a prior overstatement of his beneficial ownership by 4,003 shares has been corrected.
Axogen, Inc. Chief Innovation Officer Erick Wayne DeVinney reported equity compensation and related tax-withholding transactions. On February 26, 2026, he received grants of 23,000 restricted stock units and 33,780 shares of common stock as awards, at no cash cost per share.
The filing also shows dispositions of 11,276 shares and 10,702 shares of common stock identified as tax-withholding transactions, used to cover tax liabilities from the vesting of performance stock units and restricted stock units. Footnotes clarify that no shares were sold by the reporting person in these dispositions.
Each restricted stock unit represents one share of Axogen common stock. The RSU award is scheduled to fully vest on February 26, 2030, with 50% vesting on February 26, 2028 and an additional 25% vesting each 12 months thereafter, with shares delivered upon each vesting date.